July 3, 2007
Cytyc, Hologic wait out antitrust period
By Matthew L. Brown
Medical device and diagnostic company Cytyc Corp. of Marlborough and medical imaging and device manufacturer Hologic Inc. of Bedford said they've taken another step toward finalizing their $6.2 billion merger.
The companies said they had successfully endured the waiting period required by the Hart-Scott-Rodino Antitrust Improvement Act of 1976, and they don't believe the pending deal is subject to any further antitrust scrutiny.
The merger was announced in late May, and still must pass muster with shareholders of each company. If done, the deal would pay Cytyc shareholders $16.50 in cash for their company common stock, and give them 0.52 shares of Hologic common stock.
Both companies focus on women's health and cancer screening.
The companies said they had successfully endured the waiting period required by the Hart-Scott-Rodino Antitrust Improvement Act of 1976, and they don't believe the pending deal is subject to any further antitrust scrutiny.
The merger was announced in late May, and still must pass muster with shareholders of each company. If done, the deal would pay Cytyc shareholders $16.50 in cash for their company common stock, and give them 0.52 shares of Hologic common stock.
Both companies focus on women's health and cancer screening.
WBJ Web Partners
Most Recent
Most Recent
0 Comments